Patient guide · Reviewed June 2026
Hit a GLP-1 Weight Loss Plateau? What Australian Patients Should Do Next
You stepped on the scales this week and the number was the same as last week. And the week before. After months of steady progress on Ozempic, Wegovy, or Mounjaro, the weight has stopped moving.
A GLP-1 plateau is one of the most common experiences patients report — and one of the most misunderstood. It is not a sign the medication has stopped working. It is not a reason to stop taking it. It is a predictable physiological response that most patients encounter, and there are clear, evidence-based steps to take.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
Why Plateaus Happen on GLP-1 Medications
GLP-1 plateaus typically occur after 6–12 months when your body adapts to the medication's effects. Understanding why is the first step to knowing what to do.
GLP-1 plateaus typically occur after 6–12 months when your body adapts to the medication's effects. Understanding why is the first step to knowing what to do.
Metabolic adaptation: When you lose weight, your body's total energy expenditure decreases proportionally. A person who has lost 15kg needs fewer calories to maintain their new weight than they did at their starting weight. What produced a calorie deficit at the start of therapy may now only maintain current weight. This is normal biology — not medication failure.
Dose plateau: GLP-1 medications are titrated gradually over months. If your weight loss stalls during dose escalation, the next scheduled dose increase may be what restarts progress. Discuss your titration schedule with your prescribing doctor.
Gradual caloric creep: Appetite suppression is strongest in the early months of GLP-1 therapy. Over time, appetite may partially return at a stable dose. Small, unintentional increases in food intake — a slightly larger portion here, a snack there — can offset weight loss at a smaller body weight.
Muscle loss: Rapid weight loss on GLP-1 medications can include muscle loss if protein intake is inadequate. Less muscle means a lower resting metabolic rate, which reduces the calorie deficit over time. This is a manageable cause of plateau — and why adequate protein intake (1.2–1.6g per kilogram of body weight per day) matters so much on GLP-1 therapy.
What to Do First — Before Seeing Anyone
Review your protein intake honestly. The most common nutritional cause of GLP-1 plateau is inadequate protein. At the dose of appetite suppression most patients experience, eating enough protein to preserve muscle requires deliberate effort. Calculate your current protein target (1.2–1.6g × your body weight in kg) and track your actual intake for one week. Most patients who do this discover a gap.
Assess your activity level — specifically resistance training. Resistance training is particularly valuable during GLP-1 therapy because it preserves muscle mass, which is critical for maintaining metabolic rate during weight loss. Cardio alone is less effective for breaking a plateau than a combination of resistance training and cardio. Two resistance training sessions per week provide sufficient stimulus for most patients.
Be honest about caloric drift. As appetite suppression slightly reduces over time, food intake can gradually increase without you noticing. A week of accurate food tracking — not perfect eating, just accurate recording — reveals whether caloric intake has drifted upward.
Patient guide · Reviewed June 2026
When to See Your Doctor
If self-assessment and the above steps do not restart weight loss within 4–6 weeks, see your GP or prescribing doctor. Specifically:
If self-assessment and the above steps do not restart weight loss within 4–6 weeks, see your GP or prescribing doctor. Specifically:
Discuss your dose: If you are not at the maximum dose for your medication, a dose increase within safe parameters may restart weight loss. Clinical trials show a clear dose-response effect for both semaglutide and tirzepatide. A prescriber will assess safety, tolerance, and overall progress before adjusting. Do not increase dose without clinical guidance.
Consider switching medications: If you have been on Ozempic (semaglutide 1mg) for weight management and have hit a plateau, switching to Wegovy (semaglutide 2.4mg) or Mounjaro (tirzepatide) may provide renewed progress. Mounjaro targets both GLP-1 and GIP receptors simultaneously, which may produce renewed weight loss in patients whose response to semaglutide has diminished.
Rule out medical causes: Thyroid dysfunction, insulin resistance, and other medical conditions can blunt weight loss response. A blood panel — TSH, fasting glucose, HbA1c, insulin — can identify treatable contributing factors.
Request a dietitian referral: A GP can refer you to an Accredited Practising Dietitian under a Chronic Disease Management Plan, providing up to five Medicare-subsidised consultations per year. An APD calculates your specific protein requirements, identifies caloric drift, and designs a meal plan that breaks the plateau sustainably.
When a Plateau Might Signal Something Else
Most GLP-1 plateaus are straightforward metabolic adaptation. But discuss with your doctor if:
- The plateau began very early — within 8 weeks of starting therapy. This may indicate you are at a lower dose than optimal for your weight, or a medical cause is interfering.
- You have gained weight rather than plateaued. Weight gain during active GLP-1 therapy warrants investigation.
- The plateau coincides with significant life stress, poor sleep, or changes in other medications.
Patient guide · Reviewed June 2026
Should You Stop Taking Your GLP-1 Medication?
No — not because of a plateau. GLP-1 medications should not be discontinued because weight loss has stalled. The medications continue providing cardiovascular,…
No — not because of a plateau. GLP-1 medications should not be discontinued because weight loss has stalled. The medications continue providing cardiovascular, liver, kidney, and metabolic benefits even when weight loss has plateaued. Stopping because of a plateau typically leads to weight regain, and restarting later is harder on both the body and the budget.
A plateau means your dose or approach may need adjustment — not that the medication should stop. Work through the options above with your prescribing doctor before making any decisions about discontinuing.
The Bariatric Option — When GLP-1 Has Reached Its Limit
For some patients — particularly those with a starting BMI above 45, or those who have lost less than 10% of body weight after a full titration schedule — GLP-1 therapy may not be producing sufficient results. In these cases, a bariatric surgery consultation is appropriate.
Bariatric surgery and GLP-1 therapy are not mutually exclusive. Increasingly, they are used in combination — surgery for initial significant weight loss, GLP-1 for long-term maintenance. A bariatric surgeon can assess whether surgery is appropriate and what procedure would best suit your clinical profile.
Patient guide · Reviewed June 2026
Finding Support in Australia
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Why has my weight loss stalled on Ozempic?
A plateau on Ozempic typically reflects metabolic adaptation — as your body weight decreases, your total daily energy expenditure decreases proportionally, reducing the calorie deficit. Common contributing factors include inadequate protein intake, insufficient resistance training, gradual caloric drift, and approaching the dose ceiling for semaglutide 1mg. Discuss your dose and monitoring with your prescribing doctor.
Does hitting a plateau mean Ozempic has stopped working?
No. A plateau means your body has reached energy balance at its current weight — not that the medication has lost effect. GLP-1 medications continue providing cardiovascular, liver, and metabolic benefits even when weight loss has paused. A dose adjustment or lifestyle modification typically restarts progress.
Should I switch from Ozempic to Mounjaro if I've plateaued?
Switching from semaglutide to tirzepatide is an option worth discussing with your doctor. Tirzepatide's dual GLP-1/GIP mechanism may produce renewed weight loss in patients whose response to semaglutide has plateaued. Clinical trials showed tirzepatide produced approximately 20% weight loss versus 14% for semaglutide in direct comparison.
How long does a GLP-1 plateau last?
With appropriate intervention — dose adjustment, dietary modification, resistance training — most patients break through a plateau within 4–8 weeks. A plateau that persists beyond 8 weeks despite intervention warrants medical review.
What protein intake do I need on GLP-1 medications?
1.2–1.6g of protein per kilogram of body weight per day. On suppressed appetite this requires deliberate prioritisation — eat protein first at every meal before other foods. Inadequate protein during GLP-1 therapy leads to muscle loss, which reduces metabolic rate and contributes to plateau.
Can a plateau on GLP-1 be caused by a medical condition?
Yes. Thyroid dysfunction, uncontrolled insulin resistance, and certain medications (corticosteroids, some antidepressants) can blunt weight loss response. A standard blood panel — TSH, fasting glucose, HbA1c — can identify these factors.
Sources: Doctronic GLP-1 plateau guide May 2026; Ubie Health medically approved next steps February 2026; HealthOn GLP-1 plateau March 2026; Exploretreatments GLP-1 plateau what to do February 2026; Gobymeds GLP-1 plateau April 2026.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.